Stopping a GLP-1 abruptly and expecting maintenance of weight loss is not realistic. Even replacing it with a standard “eat less, move more” plan is not sufficient as it ignores what we know about hunger regulation and metabolic adaptation. A reduced-calorie diet and 30 minutes of daily walking, while helpful, are rarely sufficient to overcome the physiological forces defending prior weight.
Weight maintenance after significant loss requires managing cravings, psychological hunger cues, sleep, stress, food environment, and daily realities that generic advice doesn’t address.
Without that support, weight regain isn’t a personal shortcoming. It is a predictable outcome.
The marketplace problem
As demand for GLP-1s has surged, so has a marketplace that treats them like consumer products rather than chronic disease therapies. Recent national news coverage has raised concerns about patients receiving powerful injectable medications after completing brief online questionnaires, with minimal ongoing clinical oversight. Some platforms operate on pay-per-prescription models that prioritize volume over continuity.
Telehealth itself is not the problem. Used responsibly, it has been integral to expanding access to obesity care for people who previously faced stigma, long wait times, or geographic barriers. But obesity medications are complex and affect appetite regulation, digestion, metabolism, and cardiometabolic risk. Decisions about dosing, side effects, and whether or when to discontinue should be made in ongoing partnership with a licensed medical provider, not automated algorithms.
For patients considering telehealth-based care, the distinction matters. Look for services that offer direct access to licensed clinicians, longitudinal care relationships, and individualized treatment plans rather than one-size-fits-all protocols. Weight loss is never just about a prescription. Lasting health requires real medical oversight and a long-term plan.
What comes next
The next phase of the GLP-1 conversation should not center on whether patients or the medication “failed” when weight returns. It should ask better questions: Who benefits from long-term treatment? Who might safely transition off, and under what conditions? What does evidence-based maintenance support actually look like?
Until we treat obesity as the chronic disease it is, rather than a short-term problem to solve and move past, we will keep mistaking predictable biology for personal failure. The real question facing medicine is not whether these medications work. It is whether we are willing to use them responsibly, with the kind of long-term, individualized care that chronic disease management requires.
Jessica Duncan is an obesity medicine physician.
